Contents of this article
The endocrine system relies on peptides as its primary messengers, orchestrating communication between glands, organs, and tissues. From hypothalamic signals controlling pituitary activity to modern peptide-based drugs reshaping diabetes, cardiovascular, fertility, and bone care, these short chains of amino acids are central to hormone signaling. Advances in receptor pharmacology and peptide delivery technologies have extended their role beyond classical physiology, placing peptides at the heart of contemporary endocrinology.
Peptides in endocrine physiology
Peptides, though shorter than proteins, play critical roles as signaling molecules functioning as hormones and neuromodulators. They are synthesized as pre-prohormones and undergo cleavage and post-translational modifications to generate active forms capable of binding specific receptors, primarily G protein-coupled receptors (GPCRs) or receptor tyrosine kinases.
Hypothalamic–pituitary axes
The hypothalamus secretes peptide hormones such as corticotropin-releasing hormone (CRH), thyrotropin-releasing hormone (TRH), and gonadotropin-releasing hormone (GnRH), which stimulate pituitary secretion of ACTH, TSH, LH, FSH, and growth hormone. These regulate adrenal, thyroid, and gonadal function. Negative feedback loops such as cortisol inhibiting CRH and ACTH, maintain homeostasis.
Beyond the classic axes
Peptide hormones regulate various additional physiological processes:
- Vasopressin and natriuretic peptides manage fluid balance and blood pressure.
- Parathyroid hormone (PTH) controls calcium homeostasis and bone metabolism.
- Incretins like GLP-1 and GIP influence glucose metabolism and satiety.
Peptide therapeutics in endocrine disorders
GLP-1 receptor agonists
Semaglutide, a GLP-1 receptor agonist, has been shown to significantly reduce major adverse cardiovascular events (MACE) in patients with overweight or obesity with or without diabetes, according to the SELECT trial. Additionally, the FDA has updated its indication to include reducing cardiovascular risk and treating metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis.
Emerging multi-agonist Peptides
Tirzepatide, a dual GIP/GLP-1 receptor agonist, was approved in 2022 for type 2 diabetes and in 2023 for weight loss. It demonstrates superior glycemic control and weight reduction compared to GLP-1 agonists alone and boasts a unique receptor bias favoring GIPR and cAMP signaling pathways.
Reproductive endocrinology
Kisspeptin activates GnRH neurons and is under investigation as a novel infertility treatment, offering a more physiological alternative to traditional triggers.
Bone health
PTH analogs such as Teriparatide and Abaloparatide stimulate bone formation and reduce fracture risk, exemplifying targeted peptide interventions in osteoporosis.
Advances in Peptide delivery for the endocrine system
Innovations like oral Semaglutide (Rybelsus), depot injections, lipidation, and albumin-binding have extended peptide half-lives and improved bioavailability. These advances support weekly to monthly dosing and boost patient adherence.
Safety, access, and future perspectives
Peptide therapies are generally well tolerated; gastrointestinal side effects are common but manageable via dose escalation. High costs and limited access remain challenges. Future directions include expanding orally available peptides beyond GLP-1, developing multi-agonists, refining peptide mimetics, and advancing personalized therapy based on genetic and metabolic profiling.
Peptides serve as the primary language of the endocrine system, mediating an array of physiological functions, from metabolic control and reproduction to skeletal integrity. Therapeutic peptides such as GLP-1 agonists (e.g., Semaglutide), multi-agonists (e.g., Tirzepatide), Kisspeptin, and PTH analogs, are dramatically expanding the horizons of precision endocrine medicine. With continuous advances in receptor targeting and delivery methods, peptide-based interventions are poised to deliver highly effective and personalized treatment across endocrine-related disorders.
Research sources:
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Michael Lincoff, M.D., Kirstine Brown‑Frandsen, M.D., Helen M. Colhoun, M.D., John Deanfield, M.D., Scott S. Emerson, M.D., Ph.D., Sille Esbjerg, M.Sc., Søren Hardt‑Lindberg, M.D., Ph.D., G. Kees Hovingh, M.D., Ph.D., Steven E. Kahn, M.B., Ch.B., Robert F. Kushner, M.D., Ildiko Lingvay, M.D., M.P.H., Tugce K. Oral, M.D., Marie M. Michelsen, M.D., Ph.D., Jorge Plutzky, M.D., Christoffer W. Tornøe, Ph.D. and Donna H. Ryan, M.D. for the SELECT Trial Investigators. Published in NEJM 2023 | DOI: 10.1056/NEJMoa2307563
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Qiyuan Keith Liu. Published in Frontiers in Endocrinology 2024 | DOI: 10.3389/fendo.2024.1431292
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy